Literature DB >> 34645970

Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema.

Debdulal Chakraborty1, Soumen Mondal1, Nikulaa Parachuri2, Nilesh Kumar3, Ashish Sharma4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34645970      PMCID： PMC8807620          DOI： 10.1038/s41433-021-01816-3

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  1 in total

1.  Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.

Authors:  Prashanth G Iyer; Marc C Peden; Ivan J Suñer; Nish Patel; Sander R Dubovy; Thomas A Albini
Journal:  Am J Ophthalmol Case Rep       Date:  2020-11-10
  1 in total
  1 in total

Review 1.  Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.

Authors:  Evdoxia-Maria Karasavvidou; Paris Tranos; Georgios D Panos
Journal:  Drug Des Devel Ther       Date:  2022-08-09       Impact factor: 4.319
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.